Key Person Life Insurance for Venture-Backed Startups
Investors now require it as standard protection against founder loss.
Early-stage venture-backed companies concentrate nearly all their enterprise value in a small handful of people. When a seed or Series A investor underwrites a deal, they are not primarily betting on a product roadmap or a market thesis; they are betting on two or three individuals executing against both. If one of those individuals dies or becomes incapacitated, the company's ability to deliver on the thesis that justified the valuation can disappear with them, and the capital already invested can become unrecoverable. That is why key person risk belongs in the same conversation as runway and burn rate. It is not a peripheral concern dressed up as governance diligence; it is a direct threat to the return profile of the investment itself. Investors who have priced a round around a founder's technical vision or a CEO's ability to close enterprise contracts have, whether they say so explicitly or not, priced in that person's continued presence. Key person insurance exists to make that continued presence a hedgeable risk.
From Boardroom Suggestion to Term Sheet Clause
Key person insurance used to be the kind of thing a board member might raise in passing, a prudent idea worth getting to eventually. It has since become a standard clause in term sheets, reviewed with the same seriousness as the cap table or the state of IP assignments. Investors increasingly treat the absence of a policy, or the absence of a plan to obtain one, as a governance gap flagged before a deal closes. The demand is not confined to seed rounds, where the sums are comparatively modest. Practitioners report the same clauses appearing in Series A and B term sheets, where the capital at stake is larger and investor expectations around formal risk management scale accordingly. Venture debt lenders add a second, parallel requirement: coverage structured through a collateral assignment, so that if a founder dies, the insurer pays the outstanding loan balance to the lender first, with any remainder passing to the business rather than to the founder's estate or surviving co-founders. The clause travels across both equity and debt financing. Founders should expect to encounter it regardless of which side of the capital stack they are negotiating with. None of this is paperwork to be handled quietly after the round closes. A missing or incomplete policy can delay, or in some cases block, the closing itself.
Who counts as a key person at each funding stage
Identifying a key person is not a matter of job title. The relevant test is financial impact: would the company's operations or financial stability be critically endangered if this specific person were lost? At the earliest stages, that question nearly always points to the founding CEO, and, in companies where technical differentiation is the core asset, the CTO as well. As the company matures, the answer shifts. A chief revenue officer whose personal relationships drive the majority of the pipeline may become just as critical as either founder by Series A. In a regulated sector, a chief compliance officer who holds relationships with regulators and institutional knowledge no one else in the company possesses can carry risk disproportionate to their title. The instinct in an early-stage company is often to treat everyone as indispensable, but insurers require a defensible financial justification for each person named on a policy, which forces founders to make the judgment explicit. The insured person has to consent and disclose health and lifestyle information as part of underwriting. A company cannot take out this coverage on a founder without that founder's knowledge and active cooperation.
Sizing coverage to satisfy investors and reflect actual exposure
A common shortcut sizes coverage as a multiple of the key person's salary. That approach is structurally mismatched to how early-stage companies actually operate, since founders routinely draw minimal salaries while driving a business worth many multiples of that figure. A more defensible framework combines several inputs. It accounts for the total capital raised to date, since that is what investors have already put at risk. It accounts for enough operating runway, often framed as a year or more, to let the business stabilize while a replacement is found. It accounts for the estimated cost of recruiting and onboarding a successor, which practitioners describe as a substantial multiple of the role's annual salary. And it accounts for any outstanding business loans or personal guarantees that would become due on the key person's death. Underwriting practices for startups have adapted to make this framework workable: underwriters now look at capital raised and valuation at the Seed, Series A, and Series B stages rather than insisting on historical revenue, provided the company can document its financials with enough accuracy to justify the requested limit. Term sheets will often specify a coverage floor tied to round size. Founders should treat that number as a baseline investors require, not as evidence that the exposure has been fully accounted for.
What the Payout Is For
The insurer pays the death benefit to the company as a lump sum, and the company then has discretion over how to deploy it. That discretion is the reason the policy has to be designed with the actual use cases in mind from the outset. The most immediate use is financial stability during the transition, keeping payroll funded, vendor relationships intact, and investor confidence from collapsing while a successor is found. A second use is covering the direct costs of executive search and onboarding. A third, less discussed but often decisive, is buying out the key person's equity stake, which prevents the kind of chaotic cap-table dispute that can follow a founder's death if shares pass to an estate with no operational stake in the company. A fourth is satisfying venture debt or other obligations that become immediately callable upon the individual's death. Whether the payout is tax-efficient for the company depends heavily on jurisdiction and policy structure, and that question should be worked through with a tax adviser when the policy is being designed, not after a claim has already been triggered.
Why a life-only policy leaves the most probable disruption scenario uninsured
A working-age professional is substantially more likely to experience a disabling illness or injury during their working years than to die during that same period. A policy that only pays out on death is therefore insuring the less probable event while leaving the more probable one completely exposed. Key person disability insurance exists as a distinct policy from key person life insurance, and most companies have never been offered one because their broker failed to raise it. There is a further blind spot inside disability coverage itself: insurers have historically built disability definitions around physical impairment, and have been slower to adequately address cognitive and emotional disability. That gap matters acutely for founders and senior executives, whose value to the company rests on planning, complex judgment, and the ability to navigate relationships, not on physical capacity. Founders structuring a key person program should ask the broker directly about disability coverage as a required component of the conversation, not as an optional extra to consider once life coverage is in place.
Why a policy that was right at closing can become inadequate as the company grows
A policy sized against seed-round investor obligations reflects seed-round exposure, nothing more. By Series B, the capital at risk, the obligations tied to venture debt, and the scale of the operation have all likely grown well past what the original policy was built to cover, yet many companies never go back and revisit the number once it is set. The exposures that shift are not only financial. New venture debt agreements introduce new covenants. Revenue figures grow. New hires become critical to the business in ways the original underwriting never anticipated. The list of who counts as a key person shifts as well: a CTO who was indispensable at founding may matter less three years later, while a VP of Sales hired at Series A may by then control the majority of the company's revenue relationships. The most practical fix is to treat each funding round as the natural moment to revisit coverage, since the underlying risk profile is already being scrutinized by investors during that process anyway. Aligning the insurance review to the fundraising calendar turns a task that is easy to forget into one with a built-in trigger.
The underwriting process founders should prepare for
Key person life insurance differs from coverage types like D&O or general liability in one important respect: it requires individual medical underwriting of the person being insured, not just an assessment of the company. That medical underwriting takes real time, so the process needs to begin the moment a term sheet is signed. Because the key person must personally consent and disclose health and lifestyle information, the company cannot initiate this process unilaterally; founder buy-in has to be secured early. For startups specifically, underwriters have adjusted their inputs to work from capital raised and valuation at each funding stage rather than demanding a revenue history the company does not yet have, but that adjustment only works if the company can produce detailed, accurate financial documentation to support the requested coverage limit. The most common failure founders run into is treating this insurance requirement as administrative cleanup to be handled after the round closes, rather than as a parallel workstream that has to start the same day the term sheet is signed.
How startup-focused carriers are changing the market
Much of the friction historically associated with key person coverage came from an underwriting culture built for established, revenue-generating businesses with years of financial history to examine. That culture was a poor fit for pre-revenue and early-revenue startups, and it is part of why founders have often experienced delays and documentation demands disproportionate to the size of the policy being requested. The emergence of venture-native insurance carriers is changing that picture. Corgi, founded in 2024 and based in San Francisco, received regulatory approval to operate as a licensed insurance carrier in July 2025, and by June 2026 had reached a valuation of $2.6 billion following a Series B1 round. A company built specifically around startup risk reaching that scale of investment signals that serious capital is now being directed at solving the friction between startups and underwriting frameworks designed for mature companies. For founders, the practical upshot is that the market for startup-appropriate coverage, including underwriting that accepts pre-revenue valuations and VC-stage financials as legitimate inputs, is considerably more developed than it was just two or three years ago. The most effective way to take advantage of that development is to work with a broker who specializes in venture-backed companies. A specialist broker understands how to present a pre-revenue company's financials in the terms underwriters now accept, and knows which carriers can move fast enough to meet a term sheet's closing timeline, keeping coverage a non-issue instead of a bottleneck at the worst possible moment.
What founders should do before the term sheet arrives
The clearest advantage available to a founder heading into a funding negotiation is to have already done the work before anyone asks for it. Identify the key people in the business using the financial impact test, not by title or seniority. Build a coverage figure using the multi-input method, combining total capital raised, the runway needed to stabilize operations, realistic replacement costs, and any outstanding obligations, rather than reaching for a salary multiple that understates the company's actual exposure. Confirm that the founder or founders in question are prepared to consent to underwriting and disclose health information before a broker is even engaged, since that step cannot be skipped or delegated. Ask the broker directly whether disability coverage is part of the conversation, not only life coverage. Plan to revisit the policy at each subsequent funding round, timed to the due diligence process that is already underway. Founders who arrive at the negotiating table with this already handled, or at minimum with a specialist broker engaged and underwriting already in motion, remove a real closing risk and avoid the four-to-six-week underwriting delay that can otherwise hold up a round. More than that, they demonstrate to the investors across the table that the single largest unhedged risk in an early-stage company, the loss of the people the entire valuation depends on, has already been taken seriously.
